First In Human Study of CX-2051 in Advanced Solid Tumors

NCT06265688 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult

Interventions

DRUG: CX-2051
DRUG: Bevacizumab

Sponsor

CytomX Therapeutics